Optimization of Blood Pressure Treatment with Fixed-combination Perindopril/amlodipine in Patients with Arterial Hypertension

Overview

Journal Clin Drug Investig

Date 2012 Aug 11

PMID 22877321

Citations 6

Authors

Robert Hatala

Daniel Pella

Katarina Hatalova

Rastislav Sidlo

Affiliations

Soon will be listed here.

Abstract

Background: Fixed-dose combination treatments using an angiotensin-converting enzyme (ACE) inhibitor, such as perindopril, plus a calcium channel blocker (CCB), such as amlodipine, have been endorsed by guidelines because they improve blood pressure control and cardiovascular outcomes in hypertensive patients, while being well tolerated and well adhered to by patients.

Objective: This study aimed to assess the blood pressure-lowering effects of fixed-combination perindopril/amlodipine in patients previously treated with an ACE inhibitor and/or a CCB.

Methods: This was a prospective, real-life, open-label, longitudinal, phase IV study conducted in 223 outpatient medical centres across Slovakia. 2132 previously treated patients whose hypertension was insufficiently controlled at baseline or who tolerated treatment poorly were included. Patients were treated for 3 months with fixed-combination perindopril/amlodipine 5 mg/5 mg, 5 mg/10 mg, 10 mg/5 mg and 10 mg/10 mg. The main outcome measure was a reduction in mean systolic blood pressure (SBP) and diastolic blood pressure (DBP) and achievement of blood pressure targets (SBP/DBP <140/90 mmHg or <130/80 mmHg for patients with type 2 diabetes mellitus or high cardiovascular risk).

Results: After 3 months of treatment, mean ± SD SBP/DBP had decreased from 158.5 ± 17.5/93.6 ± 9.8 mmHg to 132.9 ± 10.6/80.7 ± 6.2 mmHg (p < 0.0001). In patients with grade 3 hypertension, mean ± SD changes from baseline in SBP/DBP were -45.4 ± 16.4/-20.0 ± 11.5 mmHg after 3 months (p < 0.0001). Blood pressure targets were reached by 74% of the overall patient population, 84% of patients with grade 1 hypertension, and 52% of difficult-to-treat patients with grade 3 hypertension. This treatment was associated with a 58% reduction in the number of patients with amlodipine-related ankle oedema compared with baseline.

Conclusion: Fixed-combination perindopril/amlodipine was well tolerated and resulted in statistically significant and clinically meaningful decreases in blood pressure.

Citing Articles

Efficacy and safety of sympathetic mapping and ablation of renal nerves for the treatment of hypertension (SMART): 6-month follow-up of a randomised, controlled trial.

Wang J, Yin Y, Lu C, Lu Z, Hu J, Wang Y EClinicalMedicine. 2024; 72:102626.

PMID: 38756107 PMC: 11096821. DOI: 10.1016/j.eclinm.2024.102626.

Single-pill fixed-dose drug combinations to reduce blood pressure: the right pill for the right patient.

Sarzani R, Laureti G, Gezzi A, Spannella F, Giulietti F Ther Adv Chronic Dis. 2022; 13:20406223221102754.

PMID: 35769133 PMC: 9235298. DOI: 10.1177/20406223221102754.

Implementing Single-Pill Combination Therapy for Hypertension: A Scoping Review of Key Health System Requirements in 30 Low- and Middle-Income Countries.

Bruyn E, Nguyen L, Schutte A, Murphy A, Perel P, Webster R Glob Heart. 2022; 17(1):6.

PMID: 35174047 PMC: 8796691. DOI: 10.5334/gh.1087.

Amlodipine as an antiischemic drug is superior to long acting nitrates.

Koracevic G, Dakic S, Velickovic-Radovanovic R, Apostolovic S, Krstic N, Tasic I Open Med (Wars). 2017; 10(1):50-56.

PMID: 28352677 PMC: 5152957. DOI: 10.1515/med-2015-0011.

Switching from a Free Association of Perindopril/Amlodipine to a Fixed-Dose Combination: Increased Antihypertensive Efficacy and Tolerability.

Hatalova K, Pella D, Sidlo R, Hatala R Clin Drug Investig. 2016; 36(7):591-8.

PMID: 27113228 DOI: 10.1007/s40261-016-0404-0.

References

Ferrari R . Optimizing the treatment of hypertension and stable coronary artery disease: clinical evidence for fixed-combination perindopril/amlodipine. Curr Med Res Opin. 2008; 24(12):3543-57. DOI: 10.1185/03007990802576302. View

Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G . 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007; 25(6):1105-87. DOI: 10.1097/HJH.0b013e3281fc975a. View

Gong L, Guo J, Wang X, Liu Y, Ye X, Zhang G . Parallel comparative trial of amlodipine and nitrendipine monotherapy in patients with essential hypertension. J Hypertens Suppl. 1998; 16(4):S43-7. View

Fox K . Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003; 362(9386):782-8. DOI: 10.1016/s0140-6736(03)14286-9. View

Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield M . Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009; 27(11):2121-58. DOI: 10.1097/HJH.0b013e328333146d. View

Dahlof B, Sever P, Poulter N, Wedel H, Beevers D, Caulfield M . Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm.... Lancet. 2005; 366(9489):895-906. DOI: 10.1016/S0140-6736(05)67185-1. View

Ceconi C, Fox K, Remme W, Simoons M, Bertrand M, Parrinello G . ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res. 2006; 73(1):237-46. DOI: 10.1016/j.cardiores.2006.10.021. View

Bahl V, Jadhav U, Thacker H . Management of hypertension with the fixed combination of perindopril and amlodipine in daily clinical practice: results from the STRONG prospective, observational, multicenter study. Am J Cardiovasc Drugs. 2009; 9(3):135-42. DOI: 10.1007/BF03256570. View

Messerli F . Vasodilatory edema: a common side effect of antihypertensive therapy. Curr Cardiol Rep. 2002; 4(6):479-82. DOI: 10.1007/s11886-002-0110-9. View

10.

Wang J, Li Y, Franklin S, Safar M . Prevention of stroke and myocardial infarction by amlodipine and Angiotensin receptor blockers: a quantitative overview. Hypertension. 2007; 50(1):181-8. DOI: 10.1161/HYPERTENSIONAHA.107.089763. View

11.

Deanfield J, Detry J, LICHTLEN P, Magnani B, Sellier P, Thaulow E . Amlodipine reduces transient myocardial ischemia in patients with coronary artery disease: double-blind Circadian Anti-Ischemia Program in Europe (CAPE Trial). J Am Coll Cardiol. 1994; 24(6):1460-7. DOI: 10.1016/0735-1097(94)90140-6. View

12.

Weber M, Julius S, Kjeldsen S, Brunner H, Ekman S, Hansson L . Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet. 2004; 363(9426):2049-51. DOI: 10.1016/S0140-6736(04)16456-8. View

13.

Ogilvie R, Anand S, Roy P, De Souza S . Perindopril for control of blood pressure in patients with hypertension and other cardiovascular risk factors: an open-label, observational, multicentre, general practice-based study. Clin Drug Investig. 2008; 28(11):673-86. DOI: 10.2165/00044011-200828110-00001. View

14.

Ferrari R . Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study. Arch Intern Med. 2006; 166(6):659-66. DOI: 10.1001/archinte.166.6.659. View

15.

Navarro Estrada J, Oliveri R . Long-term efficacy of amlodipine in patients with severe coronary artery disease. J Cardiovasc Pharmacol. 1993; 22 Suppl A:S24-8. View

16.

Messerli F, Weir M, Neutel J . Combination therapy of amlodipine/benazepril versus monotherapy of amlodipine in a practice-based setting. Am J Hypertens. 2002; 15(6):550-6. DOI: 10.1016/s0895-7061(02)02926-6. View

17.

. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001; 358(9287):1033-41. DOI: 10.1016/S0140-6736(01)06178-5. View